Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer

References

• Limeres MJ, Moretton MA, Bernabeu E, Chiappetta DA, Cuestas ML. Thinking small, doing big: current success and future trends in drug delivery systems for improving cancer therapy with special focus on liver cancer. Mater Sci Eng C. 2019;95:328 – 341. doi:10.1016/j.msec.2018.11.001
   PubMed Web of Science ®Google Scholar
• Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. J Drug Target. 2013;21(10):904–913. doi:10.3109/1061186X.2013.83746924079419
   PubMed Web of Science ®Google Scholar
• Qin S-Y, Zhang A-Q, Cheng S-X, Rong L, Zhang X-Z. Drug self-delivery systems for cancer therapy. Biomaterials. 2017;112:234–247. doi:10.1016/j.biomaterials.2016.10.01627768976
   PubMed Web of Science ®Google Scholar
• Soga O, Van Nostrum CF, Fens M, et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release. 2005;103(2):341–353. doi:10.1016/j.jconrel.2004.12.00915763618
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010;624:25.20217587
   PubMedGoogle Scholar
• Markovsky E, Baabur-Cohen H, Satchi-Fainaro R. Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. J Control Release. 2014;187:145–157. doi:10.1016/j.jconrel.2014.05.02524862318
   PubMed Web of Science ®Google Scholar
• Kobiasi MA, Chua BY, Tonkin D, Jackson DC, Mainwaring DE. Control of size dispersity of chitosan biopolymer microparticles and nanoparticles to influence vaccine trafficking and cell uptake. J Biomed Mater Res A. 2012;100A(7):1859–1867. doi:10.1002/jbm.a.v100a.7
   Web of Science ®Google Scholar
• Otto DP, Otto A, de Villiers MM. Differences in physicochemical properties to consider in the design, evaluation and choice between microparticles and nanoparticles for drug delivery. Expert Opin Drug Deliv. 2015;12(5):763–777. doi:10.1517/17425247.2015.98813525516397
   PubMed Web of Science ®Google Scholar
• Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng. 2006;96(2):203–209. doi:10.1002/bit.21301
   Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18. doi:10.1016/j.colsurfb.2009.09.00119782542
   PubMed Web of Science ®Google Scholar
• Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C. 2016;60:569–578. doi:10.1016/j.msec.2015.11.067
   PubMed Web of Science ®Google Scholar
• Crucho CIC, Barros MT. Polymeric nanoparticles: A study on the preparation variables and characterization methods. Mater Sci Eng C. 2017;80:771–784. doi:10.1016/j.msec.2017.06.004
   PubMed Web of Science ®Google Scholar
• Jones MC, Leroux JC. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm. 1999;48:101–111.10469928
   PubMed Web of Science ®Google Scholar
• Opsteen JA, Cornelissen JJLM, Hest J. Block copolymer vesicles. Pure Appl Chem. 2004;76:1309–1319. doi:10.1351/pac200476071309
   Web of Science ®Google Scholar
• Yang H, Zhao X, Zhang X, Ma L, Wang B, Wei H. Optimization of bioreducible micelles self-assembled from amphiphilic hyperbranched block copolymers for drug delivery. J Polym Sci A. 2018;56(13):1383–1394. doi:10.1002/pola.v56.13
   Web of Science ®Google Scholar
• Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci. 2003;92(7):1343. doi:10.1002/jps.1039712820139
   PubMed Web of Science ®Google Scholar
• Kataoka K, Kwon G, Yokoyama M, Okano T, Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J Control Release. 1992;24:119–132.
   Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B. 2010;17:1–18. doi:10.1016/j.colsurfb.2009.09.001
   Google Scholar
• Imran M, Shah MR, Shafiullah. Chapter 10 - Amphiphilic block copolymers–based micelles for drug delivery In: Grumezescu AM, editor. Design and Development of New Nanocarriers. Norwich: William Andrew Publishing; 2018:365–400.
   Google Scholar
• Gaucher G, Dufresne M-H, Sant VP, Kang N, Maysinger D, Leroux J-C. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005;109:169–188. doi:10.1016/j.jconrel.2005.09.03416289422
   PubMed Web of Science ®Google Scholar
• Missirlis D, Kawamura R, Tirelli N, Hubbell JA. Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticles. Eur J Pharm Sci. 2006;29:120–129. doi:10.1016/j.ejps.2006.06.00316904301
   PubMed Web of Science ®Google Scholar
• Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Delivery Rev. 2001;47:113–131. doi:10.1016/S0169-409X(00)00124-1
   PubMed Web of Science ®Google Scholar
• Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA–PEG block copolymer. J Control Release. 2001;70:63–70. doi:10.1016/S0168-3659(00)00340-011166408
   PubMed Web of Science ®Google Scholar
• Pillai SA, Patel VI, Ray D, Pal H, Aswal VK, Bahadur P. Solubilization and interaction of cinnamic acid and its analogues with Pluronic® micelles. Colloids Surf A Physicochem Eng Asp. 2018;559:314–324. doi:10.1016/j.colsurfa.2018.09.074
   Web of Science ®Google Scholar
• Managa M, Britton J, Prinsloo E, Nyokong T. Effects of Pluronic F127 micelles as delivering agents on the vitro dark toxicity and photodynamic therapy activity of carboxy and pyrene substituted porphyrins. Polyhedron. 2018;152:102–107. doi:10.1016/j.poly.2018.06.031
   Web of Science ®Google Scholar
• Zhao L-Y, Zhang W-M. Recent progress in drug delivery of pluronic P123: pharmaceutical perspectives. J Drug Target. 2017;25(6):471–484. doi:10.1080/1061186X.2017.128953828135859
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release. 2008;130(2):98–106. doi:10.1016/j.jconrel.2008.04.01318534704
   PubMed Web of Science ®Google Scholar
• Akash MSH, Rehman K. Recent progress in biomedical applications of Pluronic (PF127): pharmaceutical perspectives. J Control Release. 2015;209:120–138. doi:10.1016/j.jconrel.2015.04.03225921088
   PubMed Web of Science ®Google Scholar
• Pruitt J, Husseini G, Rapoport NW. Stabilization of pluronic P-105 micelles with an interpenetrating network of N, N-diethylacrylamide. Macromolecules. 2000;33:9306–9309. doi:10.1021/ma0008544
   Web of Science ®Google Scholar
• Park KM, Bae JW, Joung YK, Shin JW, Park KD. Nanoaggregate of thermosensitive chitosan-Pluronic for sustained release of hydrophobic drug. Colloids Surf B Biointerfaces. 2008;63(1):1–6. doi:10.1016/j.colsurfb.2007.10.02418314312
   PubMed Web of Science ®Google Scholar
• Chung HJ, Go DH, Bae JW, Jung IK, Lee JW, Park KD. Synthesis and characterization of Pluronic® grafted chitosan copolymer as a novel injectable biomaterial. Current Applied Physics. 2005;5(5):485–488. doi:10.1016/j.cap.2005.01.015
   Web of Science ®Google Scholar
• Hosseinzadeh H, Atyabi F, Dinarvand R, Ostad SN. Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. Int J Nanomedicine. 2012;7:1851–1863. doi:10.2147/IJN.S2636522605934
   PubMed Web of Science ®Google Scholar
• Manaspon C, Viravaidya-Pasuwat K, Pimpha N. Preparation of folate-conjugated pluronic F127/chitosan core-shell nanoparticles encapsulating doxorubicin for breast cancer treatment. J Nanomater. 2012;2012:11. doi:10.1155/2012/593878
   Web of Science ®Google Scholar
• Domínguez-Delgado C, Fuentes-Prado E, Escobar-Chávez J, Vidal-Romero G, Rodríguez Cruz I, Díaz-Torres R. Chitosan and Pluronic^® F-127: Pharmaceutical Applications. In: Mishra MK, editor. Encyclopedia of Biomedical Polymers and Polymeric Biomaterials Florida: Taylor and Francis; 2016:1513 – 1535.
   Google Scholar
• Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 2002;22:225–250.11933019
   PubMed Web of Science ®Google Scholar
• You J, Li X, Cui FD, Du YZ, Yuan H, Hu FQ. Folate-conjugated polymer micelles for active targeting to cancer cells: preparation, in vitro evaluation of targeting ability and cytotoxicity. Nanotechnology. 2008;19(4):045102. doi:10.1088/0957-4484/19/04/045102
   Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615–1626. doi:10.1016/j.addr.2008.08.00518840489
   PubMed Web of Science ®Google Scholar
• Kim BS, Taton TA. Multicomponent nanoparticles via self-assembly with cross-linked block copolymer surfactants. Langmuir. 2007;23:2198–2202. doi:10.1021/la062692w17279714
   PubMedGoogle Scholar
• van Rooijen JM, Qiu S-Q, Timmer-Bosscha H, et al. Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2–positive breast cancer. Eur J Cancer. 2018;103:52–60. doi:10.1016/j.ejca.2018.08.00130208359
   PubMedGoogle Scholar
• Yuan P, Gao S-L. Management of breast cancer brain metastases: focus on human epidermal growth factor receptor 2-positive breast cancer. Chronic Dis Transl Med. 2017;3(1):21–32. doi:10.1016/j.cdtm.2017.01.00429063053
   PubMedGoogle Scholar
• Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–2429. doi:10.1016/S0140-6736(16)32417-527939064
   PubMed Web of Science ®Google Scholar
• Diermeier S, Horvath G, Clarke RK, Hofstaedter F, SzfllIsi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res. 2005;304:604–619. doi:10.1016/j.yexcr.2004.12.00815748904
   PubMed Web of Science ®Google Scholar
• Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:121–136. doi:10.1016/j.ctrv.2008.09.00319008049
   PubMed Web of Science ®Google Scholar
• Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM. Evolution of anti-HER2 therapies for cancer treatment. Cancer Treat Rev. 2017;59:1–21. doi:10.1016/j.ctrv.2017.06.00528715775
   PubMed Web of Science ®Google Scholar
• Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart M. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev. 2018;67:10–20. doi:10.1016/j.ctrv.2018.04.01629751334
   PubMed Web of Science ®Google Scholar
• Zhang C, Ping Q, Zhang H, Shen J. Synthesis and characterization of water-soluble O-succinyl-chitosan. Eur Polym J. 2003;39:1629–1634. doi:10.1016/S0014-3057(03)00068-5
   Web of Science ®Google Scholar
• Alexandridis P, Athanassiou V, Fukuda S, Hatton TA. Surface activity of poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide) copolymers. Langmuir. 1994;10:2604–2612. doi:10.1021/la00020a019
   Web of Science ®Google Scholar
• Pepic I, Grcic JF, Jalsenjak I. Bulk properties of nonionic surfactant and chitosan mixtures. Colloids Surf A. 2009;336:135–141. doi:10.1016/j.colsurfa.2008.11.034
   Web of Science ®Google Scholar
• Naruphontjirakul P, Viravaidya-Pasuwat K. Development of doxorubicin – core shell O-succinyl chitosan graft pluronic®127 copolymer nanoparticles to treat human cancer. Int J Biosci Biochem Bioinforma. 2011;1(2):131–136. doi:10.7763/IJBBB.2011.V1.24
   Google Scholar
• Choo ESG, Yu B, Xue J. Synthesis of poly(acrylic acid) (PAA) modified pluronic P123 copolymers for pH-stimulated release of doxorubicin. J Colloid Interface Sci. 2011;358:462–470. doi:10.1016/j.jcis.2011.03.04721474143
   PubMed Web of Science ®Google Scholar
• Kozlov MY, Melik-Nubarov NS, Batrakova EV, Kabanov AV. Relationship between pluronic block copolymer structure, critical micellization concentration and partitioning coefficients of low molecular mass solutes. Macromolecules. 2000;33:3305–3313. doi:10.1021/ma991634x
   Web of Science ®Google Scholar
• Chung YI, Kim JC, Kim YH, et al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated pluronic on tumor targeting. J Control Release. 2010;43:374–382. doi:10.1016/j.jconrel.2010.01.017
   Google Scholar
• Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release. 2001;73:255–267. doi:10.1016/S0168-3659(01)00294-211516503
   PubMed Web of Science ®Google Scholar
• Souto GD, Farhane Z, Casey A, Efeoglu E, McIntyre J, Byrne HJ. Evaluation of cytotoxicity profile and intracellular localisation of doxorubicin-loaded chitosan nanoparticles. Anal Bioanal Chem. 2016;408(20):5443–5455. doi:10.1007/s00216-016-9641-627225177
   PubMedGoogle Scholar
• Colombo P, Bettini R, Santi P, Ascentiis AD, Peppas NA. Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport. J Control Release. 1996;39:231–237. doi:10.1016/0168-3659(95)00158-1
   Web of Science ®Google Scholar
• Heller J. Biodegradable polymers in controlled drug delivery. Crit Rev Ther Drug. 1984;1:39–90.
   PubMedGoogle Scholar
• Stromhaug PE, Berg TO, Gjoen T, Seglen PO. Differences between fluid-phase endocytosis (pinocytosis) and receptor-mediated endocytosis in isolated rat hepatocytes. Eur J Cell Biol. 1997;73(1):28–39.9174669
   PubMed Web of Science ®Google Scholar
• Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14(1):1–16. doi:10.1146/annurev-bioeng-071811-15012422524388
   PubMedGoogle Scholar
• Wileman T, Harding C, Stahl P. Receptor-mediated endocytosis. Biochem J. 1985;232(1):1. doi:10.1042/bj23200012867759
   PubMedGoogle Scholar
• Decuzzi P, Ferrari M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials. 2007;28(18):2915–2922. doi:10.1016/j.biomaterials.2007.02.01317363051
   PubMed Web of Science ®Google Scholar
• Cai H, Liang Z, Huang W, Wen L, Chen G. Engineering PLGA nano-based systems through understanding the influence of nanoparticle properties and cell-penetrating peptides for cochlear drug delivery. Int J Pharm. 2017;532(1):55–65. doi:10.1016/j.ijpharm.2017.08.08428870763
   PubMedGoogle Scholar
• Srinophakun P, Thanapimmetha A, Plangsri S, Vetchayakunchai S, Saisriyoot M. Application of modified chitosan membrane for microbial fuel cell: roles of proton carrier site and positive charge. J Clean Prod. 2017;142:1274–1282. doi:10.1016/j.jclepro.2016.06.153
   Web of Science ®Google Scholar
• Kanazaki K, Sano K, Makino A, et al. Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging. Nanomedicine. 2015;11(8):2051–2060. doi:10.1016/j.nano.2015.07.00726238078
   PubMedGoogle Scholar
• AshaRani PV, Hande MP, Valiyaveettil S. Anti-proliferative activity of silver nanoparticles. BMC Cell Biol. 2009;10:1–14. doi:10.1186/1471-2121-10-119134226
   PubMed Web of Science ®Google Scholar
• Chithrani BD, Chan WCW. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Letter. 2007;7:1542–1550. doi:10.1021/nl070363y
   PubMed Web of Science ®Google Scholar
• Thurn KT, Arora H, Paunesku T, et al. Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells. Nanomedicine. 2011;7:123–130. doi:10.1016/j.nano.2010.10.01220887814
   PubMed Web of Science ®Google Scholar
• Miller CC. The Stokes-Einstein law for diffusion in solution. Proc R Soc London Ser A Containing Pap Math Phys Charact. 1924;106(740):724–749.
   Google Scholar
• Yadav JS, Das PP, Reddy TL, et al. Sub-cellular internalization and organ specific oral elivery of PABA nanoparticles by side chain variation. J Nanobiotechnology. 2011;9(1):10. doi:10.1186/1477-3155-9-1021443763
   PubMedGoogle Scholar
• Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC Jr. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res. 2000;6:260–270.10656457
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18:977–984. doi:10.1093/annonc/mdl47517229773
   PubMed Web of Science ®Google Scholar
• Park JW, Kirpotin DB, Hong K, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001;74:95–113. doi:10.1016/S0168-3659(01)00315-711489487
   PubMed Web of Science ®Google Scholar
• Shi M, Ho K, Keating A, Shoichet MS. Doxorubicin-conjugated immuno-nanoparticles for intracellular anticancer drug delivery. Adv Funct Mater. 2009;19:1–8.
   Web of Science ®Google Scholar
• Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi AA, Dinarvand R. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int J Nanomedicine. 2011;6:1977–1990. doi:10.2147/IJN.S2152321976974
   PubMed Web of Science ®Google Scholar